Physician profile
David J Johnson
NPI 1215933247
$1,036.39
in general payments reported to CMS, 2019-2025
28 companies · $84.12 in 2025
The $84.12 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $83.15 · 2022: $40.54 · 2023: $130 · 2024: $336 · 2025: $84.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $151.81 | 2019-2025 | |
| Amarin Pharma, INC. | $118.50 | 2019 | |
| Medtronic, INC. | $111.67 | 2024 | Intellis Adaptivestim |
| Amgen INC. | $111.33 | 2019-2025 | Evenity, Prolia, Prolia |
| Glaxosmithkline, LLC. | $76.10 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $61.40 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $47.74 | 2019-2024 | |
| Inspire Medical Systems, INC. | $47.63 | 2023-2024 | Inspire |
| Abbott Laboratories | $42.78 | 2022-2024 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $39.19 | 2019 | |
| Lilly USA, LLC | $31.25 | 2024 | Zepbound, Jardiance, Mounjaro |
| Exact Sciences Corporation | $30.99 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $26.89 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $25.11 | 2019 | |
| Nevro Corp. | $24.73 | 2024 | Senza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15.18 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.03 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $13.33 | 2020 | |
| Mylan Specialty L.P. | $12.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.31 | 2020 | |
| Novo Nordisk INC | $11.68 | 2019 | |
| Endogastric Solutions, INC | $10.24 | 2023 | Esophyx |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.